Previous 10 | Next 10 |
home / stock / nrx:cc / nrx:cc news
Calgary, Alberta--(Newsfile Corp. - August 9, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the " Company " or " NurExone "), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, released excerpts fr...
Calgary, Alberta--(Newsfile Corp. - July 25, 2022) - NurExone Biologic Inc. (TSXV: NRX) ("NurExone" or the "Company"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal injuries and other Central Nervous System ("CNS") indications, is...
Calgary, Alberta--(Newsfile Corp. - July 19, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal injuries and other ...
Polyrizon will be entitled for up to $3.35 million in addition to future royalties Tel Aviv, Israel, July 18, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies, and electric vehicle ...
Developing the first-of-its-kind technology drug platform for a bio-guided exosome-based product known as ExoTherapy to treat trauma to the spinal cord, brain and other central nerve system indications Global spinal cord injury therapeutics market expected to reach US$9.61 billion by 2028 E...
"ExoTherapy", NurExone's proprietary Exosome siRNA loaded product, is being developed to recover functionality in patients with traumatic spinal cord injuries Calgary, Alberta--(Newsfile Corp. - July 11, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) ...
Bnei-Brak, Israel--(Newsfile Corp. - July 7, 2022) - NurExone Biologic Inc. (TSXV: NRX) ("NurExone" or the "Company"), a leading pharmaceutical company that develops innovative exosome-based treatments, is pleased to announce that the Company will host an investor webinar on Thursday, July 14,...
Bnei-Brak, Israel--(Newsfile Corp. - July 6, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (" NurExone " or the " Company ") is pleased to announce that it has retained the services of Thesis Capital Inc. (" Thesis ") of Toronto, Ontario, a leading ca...
NurExone Biologic Inc. Opens the Market Canada NewsWire TORONTO , July 4, 2022 /CNW/ - Representatives from NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX) and their team joined Yossi Boker , TMX Head of Business Development, Israel...
Bnei-Brak, Israel--(Newsfile Corp. - June 22, 2022) - NurExone Biologic Inc. (formerly, EnerSpar Corp.) (TSXV: NRX) (" NurExone " or the " Company ") is pleased to announce that, further to its press release of June 15, 2022 announcing the closing of its reverse takeover transaction, it wi...
News, Short Squeeze, Breakout and More Instantly...
NurExone Biologic Inc. Company Name:
NRX:CC Stock Symbol:
TSXVC Market:
NurExone Biologic Inc. Website:
TORONTO and HAIFA, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce the preliminary results from a small-scale cont...
TORONTO and HAIFA, Israel, July 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, is pleased to announce two significant updates aimed at ad...
TORONTO and HAIFA, Israel, June 28, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, is pleased to announce a pre-clinical study to explore the...